FDA warns against epilepsy drug valproate for pregnant women

The FDA, in a warning issued Thursday, said that women who took valproate products for epilepsy and psychiatric problems during pregnancy increased the risk that their babies would have developmental delays, compared with women who took other anti-seizure drugs. Medical providers should "weigh the benefits and risks of valproate when prescribing this drug to women of childbearing age, particularly when treating a condition not usually associated with permanent injury or death," the FDA said. "Alternative medications that have a lower risk of adverse birth outcomes should be considered."

View Full Article in:

HealthDay News · Los Angeles Times (tiered subscription model)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
PacificSource
Boise, ID